TY - JOUR
T1 - Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer
AU - Perez, Edith A.
AU - Geoffroy, Francois J.
AU - Hillman, Shauna
AU - Johnson, Elizabeth A.
AU - Farr, Gist H.
AU - Tazelarr, Henry D.
AU - Hatfield, Alan K.
AU - Krook, James E.
AU - Maillard, James A.
AU - Levitt, Ralph
AU - Marks, Randolph S.
N1 - Funding Information:
This study was supported in part by Public Health Service grants CA-25224, CA-37404, CA-35113, CA-35272, CA-35195, CA-35269, CA-63849, CA-37417, CA-35101, CA-35415, CA-63848, CA-35103, CA-52352 and CA-60276 from the National Cancer Institute Department of Health and Human Services.
PY - 2004/6
Y1 - 2004/6
N2 - Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9%, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3% at 6 months and 41.8% at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.
AB - Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9%, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3% at 6 months and 41.8% at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.
KW - Etoposide
KW - Oral chemotherapy
KW - Paclitaxel
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=2342537018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342537018&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2003.12.002
DO - 10.1016/j.lungcan.2003.12.002
M3 - Article
C2 - 15140548
AN - SCOPUS:2342537018
SN - 0169-5002
VL - 44
SP - 347
EP - 353
JO - Lung Cancer
JF - Lung Cancer
IS - 3
ER -